While our studies indicate how CDX2 downregulation-driven transcriptional state may select for BRAF mutation in proximal colon cancers, it is intriguing what the key dependencies for KRAS mutation-driven tumor development are, and why KRAS mutations tend to occur less frequently than BRAF in CIMP-H cases. This evidence concerns the gene CDX2 and malignant colon neoplasm.